Roche Reports Positive Results for Hemophilia Drug in Kids

Apr 17, 2017

Roche says that its emicizumab drug for treating hemophilia A showed positive interim results in a phase III study with children under 12 years old.

"At this interim analysis after a median of 12 weeks of treatment, emicizumab prophylaxis showed a clinically meaningful reduction in the number of bleeds over time," Roche said in a statement.

Roche is hoping that ACE910 will compete with more traditional treatments from Novo Nordisk and Shire.

Read the Roche press release

 

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments